BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14971289)

  • 1. [Conservative treatment of chronic obstructive arterial disease with iloprost and physical training: assessment of results in 5 years of a study with 360 patients].
    Apperti M; Masella A; Sabia D; Verde I
    Ann Ital Chir; 2003; 74(4):453-7. PubMed ID: 14971289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
    Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
    Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a conservative treatment with iloprost in severe peripheral occlusive arterial disease (POAD). GISAP Study.
    Int Angiol; 1994 Mar; 13(1):70-4. PubMed ID: 7521384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
    Maksimović ZV
    Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term and long-term effects of one-week treatment with intravenous iloprost in critical limb ischemia patients (Leriche-Fontaine stage III and IV).
    Meini S; De Franco V; Auteri A; Setacci C; Di Renzo M; Pieragalli D
    Int Angiol; 2005 Mar; 24(1):64-9. PubMed ID: 15877001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tolerance and therapeutic results of iloprost in obliterative arteriopathy in lower limbs at the severe chronic ischemia stage. A retrospective study of 29 consecutive cases].
    Duthois S; Cailleux N; Lévesque H
    J Mal Vasc; 2000 Feb; 25(1):17-26. PubMed ID: 10705132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloprost infusion in diabetic patients with peripheral arterial occlusive disease and foot ulcers.
    Mirenda F; La Spada M; Baccellieri D; Stilo F; Benedetto F; Spinelli F
    Chir Ital; 2005; 57(6):731-5. PubMed ID: 16400768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between intravenous iloprost and vasoactive drugs in limb ischemia IIB severe. A retrospective analysis.
    Di Salvo MM; Ardita G; Giani L; Mugno F; Stevenazzi F; Mazzone A
    Minerva Cardioangiol; 2006 Jun; 54(3):377-81. PubMed ID: 16733512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia?
    Melillo E; Nuti M; Pedrinelli R; Buttitta F; Balbarini A
    Minerva Cardioangiol; 2006 Aug; 54(4):481-98. PubMed ID: 17016419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost.
    Balzer K; Bechara G; Bisler H; Clevert HD; Diehm C; Heisig G; Held K; Mahfoud Y; Mörl H; Rücker G
    Int Angiol; 1991; 10(4):229-32. PubMed ID: 1724669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects of prostanoid therapy. Preliminary results.
    Castagno PL; Di Molfetta L; Merlo M; Barile G; Violato F; Buzzacchino A; Ponzio F
    Minerva Cardioangiol; 2000; 48(1-2):9-18. PubMed ID: 10829583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group.
    Beischer W; Dembski JC; Gruss JD; Hofgärtner F; Horsch A; Horsch S; Kuhlmann HW; Loose DA; Mietaschk A; Schwilden ED; Spengel F; Spitzer W; Staben P; Stallkamp B; Stürzebecher CS; Tokhi M; von Bilderling P
    Vasa; 1998 Feb; 27(1):15-9. PubMed ID: 9540427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication.
    Ciuffetti G; Sokola E; Lombardini R; Pasqualini L; Pirro M; Mannarino E
    Kardiol Pol; 2003 Sep; 59(9):197-204. PubMed ID: 14618196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Modification of some prothrombotic indices after treatment with iloprost in arterial disease patients].
    Ferlito S; Bonomo T; Costa R; Di Salvo MM; Attanasio L; Finocchiaro PM; Condorelli M; Mazzone D
    Minerva Cardioangiol; 1996 Dec; 44(12):645-8. PubMed ID: 9053818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease.
    Bozkurt AK; Köksal C; Demirbas MY; Erdoğan A; Rahman A; Demirkiliç U; Ustünsoy H; Metin G; Yillik L; Onol H; Cinar B; Karaçelik M; Erdinç I; Bolcal C; Sayin AG;
    Int Angiol; 2006 Jun; 25(2):162-8. PubMed ID: 16763533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency].
    Cappelli R; Bicchi M; Arrigucci S; Boschi S; Guerrini M; Forconi S
    Minerva Cardioangiol; 1999 Mar; 47(3):81-8. PubMed ID: 10389449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.
    Opitz CF; Wensel R; Winkler J; Halank M; Bruch L; Kleber FX; Höffken G; Anker SD; Negassa A; Felix SB; Hetzer R; Ewert R
    Eur Heart J; 2005 Sep; 26(18):1895-902. PubMed ID: 15888496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new infusion method for a prostacyclin analogue].
    Pibiri L; Petruzzo P; Angius D; Ruiu G; Polo F; Rescigno A; Brotzu G
    Minerva Cardioangiol; 1997 Dec; 45(12):621-5. PubMed ID: 9577128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of iloprost in patients with severe peripheral arterial occlusive disease.
    Hildebrand M; Krause W; Oberender HA; Zurdel-Dillinger S; Jünger M; Bodenburg H
    Eicosanoids; 1990; 3(3):145-8. PubMed ID: 1700723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.